Literature DB >> 22243289

Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers.

A Castanon1, S Ferryman, J Patnick, P Sasieni.   

Abstract

OBJECTIVE: To audit pathology slide reporting in the Cervical Screening Programme in England by reviewing cytology and histology slides from women subsequently diagnosed with invasive cervical cancer.
METHODS: Between April 2007 and March 2010, 6113 women diagnosed with cervical cancer were identified. Cervical cytology and histology slides taken within 10 years of diagnosis were identified and where possible reviewed after a nationally agreed protocol. Reviewers were not blinded to the original reading of each sample. Most cytology samples before 2005 were conventional, most after 2007 liquid based.
RESULTS: Of 13,745 cytology results from women developing cervical cancer, 55% were reviewed. The review result was identical for 55% of slides. Of 3759 originally normal slides, only 45% were normal on review: 11% were inadequate, 21% low grade (borderline or mild dyskaryosis) and 23% high grade (moderate dyskaryosis or worse). Of tests originally normal taken over 5.5 years before diagnosis, 14% were upgraded to high grade compared with 37% within 3.5 years of diagnosis. Of 5159 histology specimens recorded within 10 years of diagnosis of a cancer, 3895 were reviewed. Overall, 94% of samples reviewed retained the original diagnosis. One per cent (33/3012) of cancers were downgraded and 5% (6/112) of negative samples were upgraded to cancer upon review (four of which were taken within 2 months of diagnosis). In comparison, 15% (14/91) of cervical glandular intraepithelial neoplasia (CGIN) and 12% (38/314) of cervical intraepithelial neoplasia grade 3 (CIN3) were upgraded to cancer.
CONCLUSIONS: In spite of the excellent quality of cytology in England, a high proportion of negative cytology taken up to three and a half years before diagnosis were considered to contain abnormal cells by reviewers informed of the subsequent cancer. Continuing these reviews, with a strong focus on education, will ensure a clear understanding of these slides and further reduce the risk of developing cervical cancer.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22243289     DOI: 10.1111/j.1365-2303.2011.00948.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  6 in total

1.  Histology verification demonstrates that biospectroscopy analysis of cervical cytology identifies underlying disease more accurately than conventional screening: removing the confounder of discordance.

Authors:  Ketan Gajjar; Abdullah A Ahmadzai; George Valasoulis; Júlio Trevisan; Christina Founta; Maria Nasioutziki; Aristotelis Loufopoulos; Maria Kyrgiou; Sofia Melina Stasinou; Petros Karakitsos; Evangelos Paraskevaidis; Bianca Da Gama-Rose; Pierre L Martin-Hirsch; Francis L Martin
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

2.  Primary cervical screening with high risk human papillomavirus testing: observational study.

Authors:  Matejka Rebolj; Janet Rimmer; Karin Denton; John Tidy; Christopher Mathews; Kay Ellis; John Smith; Chris Evans; Thomas Giles; Viki Frew; Xenia Tyler; Alexandra Sargent; Janet Parker; Miles Holbrook; Katherine Hunt; Penny Tidbury; Tanya Levine; David Smith; Julietta Patnick; Ruth Stubbs; Sue Moss; Henry Kitchener
Journal:  BMJ       Date:  2019-02-06

3.  Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.

Authors:  Bjørn Westre; Anita Giske; Hilde Guttormsen; Sveinung Wergeland Sørbye; Finn Egil Skjeldestad
Journal:  PLoS One       Date:  2019-11-05       Impact factor: 3.240

4.  Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot.

Authors:  Matejka Rebolj; Christopher S Mathews; Karin Denton
Journal:  Cancer Cytopathol       Date:  2022-04-04       Impact factor: 4.264

5.  Comparing the Performance of Hybrid Capture II and Polymerase Chain Reaction (PCR) for the Identification of Cervical Dysplasia in the Screening and Diagnostic Settings.

Authors:  Hung N Luu; Karen Adler-Storthz; Laura M Dillon; Michele Follen; Michael E Scheurer
Journal:  Clin Med Insights Oncol       Date:  2013-09-25

6.  Poor Cervical Cancer Screening Attendance and False Negatives. A Call for Organized Screening.

Authors:  Marta Castillo; Aurora Astudillo; Omar Clavero; Julio Velasco; Raquel Ibáñez; Silvia de Sanjosé
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.